CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $48.79B, higher than 95% of all stocks globally
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.40%Above 5Y avg (0.39%)
Annual Rate
CNY 0.20Paid annual
Payout Ratio
16.4%Sustainable
Last Ex-Dividend
May 27, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
328.54BCNY48.79B · vs all stocks (USD)
Trailing P/E
43.16xRevenue (TTM)
32.56BCNY4.84B · vs all stocks (USD)
Profit Margin
24.93%Beta
0.0410xvs all stocks
52-Week Change
-23.82%vs all stocks
Market Capitalization
328.54BCNY48.79B · vs all stocks (USD)
Enterprise Value
313.44BCNY46.55B · vs all stocks (USD)
Trailing P/E
43.16xForward P/E
30.94xPrice to Sales (TTM)
10.73xPrice to Book (MRQ)
5.56xEnterprise to Revenue
9.63xEnterprise to EBITDA
33.16xGross Margin
86.60%Profit Margin
24.93%Operating Margin
31.57%Return on Assets (TTM)
8.80%Return on Equity (TTM)
14.54%Revenue (TTM)
32.56BCNY4.84B · vs all stocks (USD)
Revenue per Share (TTM)
4.94CNYUpdated Aug 20, 2026Quarterly Revenue Growth
13.00%Gross Profit (TTM)
28.09BCNY4.17B · vs all stocks (USD)
EBITDA (TTM)
9.69BCNY1.44B · vs all stocks (USD)
Net Income (TTM)
8.12BCNY1.21B · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
21.80%Operating Cash Flow (TTM)
11.47BCNY1.70B · vs all stocks (USD)
Levered Free Cash Flow (TTM)
6.31BCNY936.83M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.2000CNYUpdated Aug 20, 2026Trailing Annual Dividend Yield
0.40%vs all stocks
5-Year Average Dividend Yield
0.39%vs all stocks
Payout Ratio
16.39%Minority Interest (Equity)
524.75MCNYFY2025 · Dec 31, 2025Revenue
31.63BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
4.36BCNYFY2025 · Dec 31, 2025Gross Profit
27.27BCNYFY2025 · Dec 31, 2025Operating Income
8.60BCNY1.28B · vs all stocks (USD)
Pre-tax Income
8.71BCNYFY2025 · Dec 31, 2025Income Tax Expense
990.62MCNYFY2025 · Dec 31, 2025Net Income
7.72BCNYFY2025 · Dec 31, 2025EBIT
8.72BCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
9.50BCNYFY2025 · Dec 31, 2025Research & Development
6.96BCNYFY2025 · Dec 31, 2025Selling, General & Administrative
7.36BCNYFY2025 · Dec 31, 2025Other Operating Expenses
263.60MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
785.39MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
14.35MCNYFY2025 · Dec 31, 2025Net Income from Continuing Operations
7.72BCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-5.95MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
6.21BCNYFY2025 · Dec 31, 2025Free Cash Flow
3.27BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
40.16BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
7.72BCNYFY2025 · Dec 31, 2025Other Non-cash Items
472.18MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-1.10BCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-883.17MCNYFY2025 · Dec 31, 2025Capital Expenditures
-2.94BCNYFY2025 · Dec 31, 2025Sale of Investments
202.49MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-2.74BCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
1.50BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-1.50BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-1.28BCNYFY2025 · Dec 31, 2025Other Financing Charges
9.07BCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
7.78BCNYFY2025 · Dec 31, 2025Shares Outstanding
6.64BSharesUpdated Aug 20, 2026Float Shares
3.77BSharesUpdated Aug 20, 2026% Held by Insiders
46.26%vs all stocks
% Held by Institutions
13.99%vs all stocks
Total Cash (MRQ)
40.64BCNY6.04B · vs all stocks (USD)
Total Cash per Share (MRQ)
6.05CNYUpdated Aug 20, 2026Total Debt (MRQ)
67.47MCNY10.02M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0010xCurrent Ratio (MRQ)
9.23xBook Value per Share (MRQ)
9.48CNYUpdated Aug 20, 2026Total Assets
69.87BCNY10.38B · vs all stocks (USD)
Total Current Assets
51.49BCNYFY2025 · Dec 31, 2025Total Liabilities
8.07BCNYFY2025 · Dec 31, 2025Total Non-current Assets
18.38BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
1.70BCNYFY2025 · Dec 31, 2025Total Current Liabilities
6.37BCNYFY2025 · Dec 31, 2025Cash
40.85BCNYFY2025 · Dec 31, 2025Cash Equivalents
101.03MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
40.96BCNYFY2025 · Dec 31, 2025Other Short-term Investments
113.84MCNYFY2025 · Dec 31, 2025Accounts Receivable
5.15BCNYFY2025 · Dec 31, 2025Inventory
2.88BCNYFY2025 · Dec 31, 2025Accounts Payable
2.27BCNYFY2025 · Dec 31, 2025Short-term Debt
30.93MCNYFY2025 · Dec 31, 2025Other Current Liabilities
3.54MCNYFY2025 · Dec 31, 2025Long-term Debt
43.31MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
1.16BCNYFY2025 · Dec 31, 2025Common Stock (Book)
6.64BCNYFY2025 · Dec 31, 2025Retained Earnings
40.17BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
61.80BCNY9.18B · vs all stocks (USD)
Treasury Stock
1.93BCNYFY2025 · Dec 31, 202552-Week Low
45.26CNYUpdated Aug 20, 202652-Week High
74.04CNYUpdated Aug 20, 202652-Week Change
-23.82%vs all stocks
Beta
0.0410xvs all stocks
50-Day MA
52.68CNYUpdated Aug 20, 2026200-Day MA
56.20CNYUpdated Aug 20, 2026Avg 10-Day Volume
92.12MSharesUpdated Aug 20, 2026Avg 30-Day Volume
91.29MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
1.22CNYUpdated Aug 20, 20264 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
Multi-Year Cash Increase With FCF And Debt Decrease
Cash up four years running while long-term debt fell for three.
Reads
How does this company use capital?
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $48.79B, higher than 95% of all stocks globallySignificant
Market cap (USD): 48,794,967,801.681Global P95: 25,614,208,870.135
Revenue is $4.84B, above the global median of $520.53MNotable
Revenue (USD): 4,836,460,144.476Global Median: 520,528,949.311
Levered free cash flow is $936.83M, above the global median of $16.24MNotable
Levered free cash flow (USD): 936,825,340.436Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Edwards Lifesciences Corporation
Tier 1ProductionApproval-Gated PipelineRule
Sun Pharmaceutical Industries Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Samsung Biologics Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Siemens Healthineers AG
Tier 1ProductionApproval-Gated PipelineRuleFlow
UCB SA
Tier 1ProductionApproval-Gated PipelineRuleRisk
Haleon plc
Tier 1ProductionApproval-Gated PipelineRuleFlow
Teva Pharmaceutical Industries Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Bayer AG
Tier 1ProductionApproval-Gated PipelineRuleFlow
Revolution Medicines Inc.
Tier 1ProductionApproval-Gated PipelineRule
Alnylam Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Sakura Development Co. Ltd.
4 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksMulti-Year Cash Increase With FCF And Debt DecreaseMulti-Year Revenue, Profit, And Income Growth
Harmony Biosciences Holdings, Inc.
4 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksMulti-Year Cash Increase With FCF And Debt DecreaseMulti-Year Revenue, Profit, And Income Growth
Federal-Mogul Goetze (India) Ltd.
4 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksMulti-Year Cash Increase With FCF And Debt DecreaseMulti-Year Revenue, Profit, And Income Growth